Relationship between thyroid-pituitary function and response to therapy in patients with recurrent breast cancer

Anticancer Research

Volumn 16, Issue 4 A, 1996, Pages 2069-2072

  Yokoe, Takao ^a   Iino, Yuichi ^a   Takei, Hiroyuki ^a   Horiguchi, Jun ^a   Koibuchi, Yukio ^a   Maemura, Michio ^a   Ohwada, Susumu ^a   Morishita, Yasuo ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

Pituitary function; Recurrent breast cancer; Thyroid function

Indexed keywords

ANTHRACYCLINE; AROMATASE INHIBITOR; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GROWTH HORMONE; LIOTHYRONINE; MEDROXYPROGESTERONE ACETATE; MITOXANTRONE; PIRARUBICIN; PROLACTIN; TAMOXIFEN; THYROTROPIN; THYROXINE;

ADULT; AGED; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; DEATH; FEMALE; FREE LIOTHYRONINE INDEX; FREE THYROXINE INDEX; GROWTH HORMONE BLOOD LEVEL; HUMAN; HYPOPHYSIS THYROID SYSTEM; LIOTHYRONINE BLOOD LEVEL; PRIORITY JOURNAL; PROGNOSIS; PROLACTIN BLOOD LEVEL; RECURRENT CANCER; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; TREATMENT FAILURE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; CYTARABINE; DISEASE PROGRESSION; DOXORUBICIN; EPIRUBICIN; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; GROWTH HORMONE; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; MITOXANTRONE; PITUITARY GLAND; PROLACTIN; RECURRENCE; TAMOXIFEN; THYROID GLAND; THYROTROPIN; THYROXINE; TRIIODOTHYRONINE;

EID: 0029740473     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Vorherr H: Thyroid function in benign and malignant breast disease. Eur J Cancer Clin Oncol 3: 255-257,1987.
2. Adami HO, Rimsten A, Thoren L, Vegelius J and Wide L: Thyroid disease and function in breast cancer patients and non-hospitalized controls evaluated by determination of TSH, T3, rT3 and T4 levels in serum. Acta Clin Scand 144: 89-97, 1978.
3. Aldinger KA, Schultz PN, Blumenschein GR and Sanaan NA: Thyroid-stimulating hormone and prolactin levels in breast cancer. Arch Intern Med 138: 1638-1648, 1978.
4. Thomas BS, Bulbrook RD, Russell MJ, Hayward JL and Millis R: Thyroid function in early breast cancer. Eur J Cancer Clin Oncol 19: 1215-1219, 1983.
5. Lemaire M and Baugnet-mahieu L: Thyroid function in women with breast cancer. Eur J Cancer Clin Oncol 22: 301-307, 1986.
6. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47: 207-214, 1981.
7. Eskin BA, Murphey SA and Dunn MR: Induction of breast cancer in altered thyroid-function. Nature 218: 1162, 1968.
8. Itoh K and Maruchi N: Breast cancer in patients with Hashimoto's thyroiditis. Lancet 6: 1119-1121, 1975.
9. Kapdi CC and Wolfe JN: Breast cancer, relationship to thyroid supplements for hypothyroidism. JAMA 236: 1124-1127, 1976.
10. Mustacchi P and Greenspan F: Thyroid supplementation for hypothyroidism. JAMA 237: 1446-1447, 1977.
11. Teas J: The consumption of seaweed as a protective factor in the etiology of breast cancer. Med Hypotheses 7: 601-613, 1981.
12. Lyons AR and Edelstyn GA: Thyroid hormone as a prophylactic agent following radical treatment of breast cancer. Brit J Cancer 19: 116-119, 1965.
13. Emery EW and Trotter WR: Triiodothyronine in advanced breast cancer. Lancet 1: 385-359, 1963.
14. Cuzick J, Allen D, Baum M, Barrett J, Clark G, Kakkar V, Melissari E, Moniz C, Moore J, Parsons V: Long term effects of tamoxifen. Biological effects of Tamoxifen Working Party. Eur J Cancer 29: 15-21, 1992.
15. Mamby CC, Love RR and Lee KE: Thyroid function test changes with adjuvant tamoxifen therapy in postmenopausal women with breast cancer. J Clin Oncol 13: 854-857, 1995.
16. Bermudez F Surks MI and Oppenheimer JH: High incidence of decreased serum triiodothyronine concentration in patients with non thyroidal disease. J Clin Endocrinol Metab 41: 27-40, 1975.
17. Watofsky L and Burman KD: Alterations in thyroid function in patients with systemic illness: the "euthyroid sick syndrome". Endoc Rev 3: 164-217, 1982.
18. Ratcliffe JG, Stack BHR, Burl RW, Radcliffe WA, Spilg WG, Cuthbert J and Kennedy RSI: Thyroid function in lung cancer. Br Med J 1: 210-212, 1978.
19. Rose DP and Davis TE: Plasma thyronine levels in carcinoma of the breast and colon. Arch Intern Med 141: 1161-1164, 1981.
20. Gershengorn MC, Reed Larsen P and Robbins J: Radioimmunoassay for serum thyroxin binding globulin: results in normal subjects and in patients with hepatocellular carcinoma. J Clin Endocrinol Metab 42: 907-901, 1976.
21. Pavelic K, Pekic B, Gabrilovac J, Bratic-Mikes V and Boranic M: Hormone changes in patients with haematological malignancies. Biomedicine 35: 181-184, 1981.
22. Lim VS : Thyroid dysfunction in chronic renal failure. J Clin Invest 60: 522-527, 1977.
23. Pittman CS, Suda AK, Chambers JB Jr, McDaniel HG, Ray GY and Preston BK: Abnormalities of thyroid hormone turnover in patients with diabetes mellitus before and after insulin therapy. J Clin Endocrinol Metab 48: 854-860, 1979.
24. Wiesinga WM : Thyroid hormones in acute myocardial infarction. Clin Endocrinol 14: 367-372, 1981
25. Chopra IJ, Huang T-S, Beredo A, Solomon DH, Teco GNC and Mead JF: Evidence for an inhibitor of extrathyroidal conversion of thyroxine to 3,5,3'-triiodothyronine in sera of patients with nonthyroidal illnesses. J Clin Endocrinol Metab 60: 666-672, 1985.
26. Kato N, Funahashi H, Ando K and Takagi H: Suppressive effect of iodine preparations of DMBA-induced breast cancer in rat. J Jpn Soc Cancer Ther 29: 582-588, 1994 (in Japanese).
27. Ando K, Funahashi H, Kato N and Takagi H: Effectiveness of iodine in suppressing tumor cell proliferation in cultivated MCF-7 human breast cancer cells. J Jpn Soc Cancer Ther 30: 628-635, 1995 (in Japanese).
28. Peake GT, Birge CA and Daughaday WH: Alterations of radioimmunoassayable growth hormone and prolactin during hypothyroidism. Endocrinology 92: 487-493, 1973.
29. Cave WT Jr, Dunn JT and Macleod RM: Effects of altered thyroid states on mammary tumor growth and pituitary gland function in rats. J Natl Cancer Inst 59: 993-999, 1977.